



# MASSACHUSETTS COVID-19 VACCINE PROGRAM

## BULLETIN

### What Massachusetts COVID-19 Vaccine Providers Need to Know Week of 7/22/2022

*Please note: Future Bulletins may decrease in frequency and will be sent out on an as needed basis as new information becomes available.*

#### LATEST NUMBERS

- As of 7/22/2022 **5,412,504** people in Massachusetts have been fully vaccinated.
- **Massachusetts has administered over 15 million doses of COVID vaccine!**

#### WHO TO VACCINATE

**Everyone ages 6 months and older** should receive a COVID-19 **primary series** vaccination for the prevention of COVID-19.

**Everyone ages 5 years and older** should receive at least 1 **booster dose** of COVID-19 vaccine if eligible (i.e., if a booster dose is FDA-approved or FDA-authorized for use in a specified population). **Recommendations for booster dose(s) vary based on age, COVID-19 vaccine product, and immunocompetence.**

The recommended schedule and use of each COVID-19 vaccine product vary by the age and immune status of the recipient. There are two vaccination schedules: one for [people who are not moderately or severely immunocompromised](#) and one for [people who are moderately or severely immunocompromised](#).

#### QUESTION OF THE WEEK

**Q: If a patient does not come back on time for the second dose of an mRNA COVID-19 vaccine, do we need to re-start the vaccine series?**

A: No. Regardless of the interval, simply administer the second dose to complete the series. The series never needs to be restarted due to a delay in the second dose.

#### WHAT TO KNOW THIS WEEK

##### **New Novavax**

On July 13, 2022, the [FDA issued an EUA](#) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

On July 19, 2022, ACIP met and voted to recommend Novavax be used as another primary series option for adults ages 18 years and older. A short time later, CDC Director Rochelle Walensky endorsed ACIP's recommendation.

Novavax is an adjuvanted protein subunit vaccine. The [CDC news release](#) states that protein subunit vaccines package harmless proteins of the COVID-19 virus alongside another ingredient called an adjuvant that helps the immune system respond to the virus in the future. Vaccines using protein subunits have been used for more than 30 years in the United

States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the United States today include those to protect against influenza and whooping cough (acellular pertussis).

The following is attributable to Dr. Walensky:

“Today, we have expanded the options available to adults in the U.S. by recommending another safe and effective COVID-19 vaccine. If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated. With COVID-19 cases on the rise again across parts of the country, vaccination is critical to help protect against the complications of severe COVID-19 disease.”

Novavax EUA, HCP: <https://www.fda.gov/media/159897/download>

Novavax EUA, Recipient: <https://www.fda.gov/media/159898/download>

### New Novavax COVID-19 Vaccine Characteristics

- Age indication: 18 years and older, primary series only
- Interval: 2 dose primary series 21 days apart
- Dose: 5 mcg SARS-CoV-2rS 50 mcg Matrix-M™ adjuvant
- Injection volume: 0.5 mL
- Preparation: Do not dilute
- Doses per vial: 10 doses
- Injection route/site: Intramuscular/deltoid
- Storage: Refrigerator 2° to 8°C (36°to 46°F) DO NOT FREEZE
- Beyond use time: 6 hours after first puncture
- Expiration: *No expiration date is printed on the vial or carton, it must be looked up on the Expiry Date Checker at <https://us.novavaxcovidvaccine.com/hcp> (also accessible from <https://www.novavaxcovidvaccine.com/> and navigating to the HCP page)*

### New Novavax Clinical Considerations

- Adults ages 18+ should receive a Novavax 2-dose primary series separated by 3–8 weeks. Currently, a booster dose using any COVID-19 vaccine is not authorized for adults in this age group who receive a Novavax primary series.
  - For people who are *not* moderately or severely immunocompromised, first and second doses of Novavax should be administered **3-8 weeks apart**.
  - For people who *are* moderately or severely immunocompromised, first and second doses of Novavax should be administered **3 weeks apart**.
- The following are **NOT** currently authorized for people receiving a Novavax COVID-19 Vaccine primary series:
  - 3rd primary dose for people who are moderately or severely immunocompromised
  - Booster dose using ANY COVID-19 vaccine after a Novavax primary series
  - CDC will provide clinical guidance for what FDA authorizes; once authorized, these doses can be added to the COVID-19 vaccination schedule

### New Novavax Vaccine Ordering and Implementation Considerations

- Additional guidance and information about ordering will be available early next week.

### New COCA Call July 28, 2pm

CDC COCA Call: Recommendations for the Novavax COVID-19 Primary Series in Adults Ages 18 and Older - July 28, 2022, 2:00 PM – 3:00 PM ET

- During this [COCA Call](#), presenters will discuss CDC’s new guidance on the Novavax COVID-19 vaccine for adults ages 18 years and older, including adults who are moderately or severely immunocompromised

### Helpful Reference Materials *(please watch for all reference materials to be updated to include Novavax)*

- [At-A-Glance COVID-19 Vaccination Schedule](#)  
A helpful pdf showing a graphic of the COVID-19 vaccine recommendations based on primary series product, age, and immune status.
- [Interim COVID-19 Immunization Schedule for 6 Months of Age and Older](#)  
A helpful pdf summarizing products, schedules, doses, boosters

- [Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](#)
- [Pfizer-BioNTech for Children who Transition from a Younger to Older Age Group](#)
- [Pfizer COVID-19 Vaccine Products At-A-Glance](#)
- [Moderna COVID-19 Vaccine At-A-Glance](#)

### Standing Orders

- CDC's Moderna COVID-19 Vaccine info (including the standing orders below)  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>
- Moderna Blue cap with magenta bordered label – 6 months through 5 years of age  
[https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/infant\\_standing-orders.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/infant_standing-orders.pdf)
- Moderna Blue cap with purple-bordered label – 6 through 11 years of age  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/6-11-standing-orders.pdf>
- Moderna Red cap with blue-bordered label – 12 through 17 years of age  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/12-17-standing-orders.pdf>
- Moderna Red cap – 18 years of age and older (updated 5/24/2022)  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/standing-orders.pdf>
- CDC's Pfizer COVID-19 Vaccine info (including the standing orders below)  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>
- Pfizer Maroon Cap: 6 months through 4 years of age  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/infant-standing-orders.pdf>
- Pfizer Orange Cap: 5 through 11 years of age (updated 5/24/2022)  
[https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer\\_PED\\_StandingOrders.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer_PED_StandingOrders.pdf)
- Pfizer Gray Cap: 12 years of age and older (updated 5/24/2022)  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/gray-cap-Pfizer-BioNTech-standing-orders.pdf>

### Preparations and Administration Summaries

- Pfizer <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/administration.html>
- Moderna <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/administration.html>

### Information for parents and caregivers:

- [COVID-19 Vaccines for Children and Teens | CDC](#)
- [Frequently Asked Questions about COVID-19 Vaccination in Children | CDC](#)
- [6 Things to Know about COVID-19 Vaccination for Children | CDC](#)
- [V-safe After Vaccination Health Checker | CDC](#)
- [COVID-19 Vaccine: Frequently Asked Questions | American Academy of Pediatrics](#)

### V-safe Reminder

Parents and guardians can easily enroll their children in the [V-safe After Vaccination Health Checker](#). V-safe provides personalized and confidential health check-ins via text messages and web surveys so that enrolled COVID-19 vaccine recipients can quickly and easily share with CDC how they feel after getting a COVID-19 vaccine.

The information collected by the tracker is an important tool as it helps CDC monitor and communicate about the safety of COVID-19 vaccines in near real time. [Click here](#) to access instructions for adding a dependent in V-safe that can be shared with parents and guardians. [Click here](#) to access V-safe information sheets in multiple languages.

### Vaccines Formulations Available for Ordering

All provider enrolled in the Massachusetts COVID-19 Vaccine Program (MCVP) are able to place routine orders for all of the following COVID-19 vaccine formulations through the Massachusetts Immunization Information System (MIIS).

Brand	NDC	NDC Description	Minimum ordering size
-------	-----	-----------------	-----------------------

-	59267-0078-04	COVID-19 (Pfizer);(PED 6m-4y) MDV10;10-pk	100
-	59267-1055-04	COVID-19 (Pfizer);(PED 5-11) MDV10;10-pk	100
-	59267-1025-04	COVID-19 (Pfizer 12+); TRIS; MDV6; 10-pack	300
COMIRNATY	00069-2025-10	COVID-19; (12+) MDV6; 10-pack	300
-	80777-0279-99	COVID-19 (Moderna);(PED 6m-5y) MDV10;10-pack	100
-	80777-0275-99	COVID-19 (Moderna);(PED 6-11 Primary   18 + Booster); MDV5; 10-pack*	100
-	80777-0273-99	COVID-19 (Moderna); MDV10; 10-pack (12+ Primary   18+ Booster)	100
-	59676-0580-15	COVID-19 (Janssen); MDV5; 10-pack	100

- Initial shipments of the Pfizer-BioNTech vaccine for children aged 6m–4 years may state “2y to <5y” or “6m to <5y” on the vial or carton labels. Please note that vials or cartons with labels that state “2y to <5y” can be used for children aged 6m through 4 years.
- Pfizer-BioNTech vaccine vial labels and cartons may also state that a vial should be discarded 6 hours after the first dilution however as stated in the EUA Fact Sheet the timeframe for use post-dilution is actually 12 hours just like orange and gray cap Pfizer vaccine formulations.

**\*Please Note:** For pediatric practices that are currently not supplying the Pfizer 5-11 year old formulation due to logistical challenges please consider supplying the new Moderna 6-11 year old formulation as it comes in only 5 dose vials, requires no reconstitution, and can be stored in a standard freezer until expiration.

## COVID-19 vaccine formulations currently approved or authorized in the United States

Table 1. COVID-19 vaccine products currently approved or authorized in the United States\*

### Pfizer-BioNTech

Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses <sup>†</sup>	
				Dose	Injection volume	Dose	Injection volume
6 months–4 years <sup>‡</sup>	Maroon	Maroon	Yes	3 µg	0.2 mL	NA	NA
5–11 years	Orange	Orange	Yes	10 µg	0.2 mL	10 µg	0.2 mL
12 years and older	Purple	Purple	Yes	30 µg	0.3 mL	30 µg	0.3 mL
12 years and older	Gray	Gray	No	30 µg	0.3 mL	30 µg	0.3 mL

### Moderna

Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses <sup>†</sup>	
				Dose	Injection volume	Dose	Injection volume
6 months–5 years	Dark blue	Magenta	No	25 µg	0.25 mL	NA	NA
6–11 years <sup>§</sup>	Dark blue	Purple	No	50 µg	0.5 mL	NA	NA
12–17 years	Red	Light blue	No	100 µg	0.5 mL	NA	NA
18 years and older	Red	Light blue	No	100 µg	0.5 mL	50 µg	0.25 mL
18 years and older	Dark blue	Purple	No	NA	NA	50 µg	0.5 mL

**Please note this footnote:** <sup>†</sup>For people ages 5–17 years, Pfizer is currently FDA-authorized for use as a booster dose in people who received Pfizer as their primary series; **Moderna is not authorized for use as a booster dose in this age group.** For people ages 18 years and older, Pfizer and Moderna can be used as a booster dose. Currently, Novavax is not authorized for booster vaccination.

## Novavax

Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses†	
				Dose	Injection volume	Dose	Injection volume
18 years and older	Royal blue	No color	No	5 µg rS and 50 µg of Matrix-M™ adjuvant	0.5 mL	NA	NA

## Janssen

Age indication	Vaccine vial cap color	Label border color	Dilution required	Primary series		Booster doses†	
				Dose	Injection volume	Dose	Injection volume
18 years and older	Blue	No color	No	5×10 <sup>10</sup> viral particles	0.5 mL	5×10 <sup>10</sup> viral particles	0.5 mL

**Abbreviation:** NA = not authorized; rS = recombinant spike protein

\*Illustrations of the different vaccine vial cap and label border colors are available from FDA for [Moderna](#) and [Pfizer-BioNTech](#) COVID-19 vaccines. Additional product-specific information is available from CDC for [all FDA-authorized or -approved vaccines](#).

†For people ages 5–17 years, Pfizer-BioNTech COVID-19 Vaccine is currently FDA-authorized for use as a booster dose in people who received Pfizer-BioNTech as their primary series; Moderna COVID-19 Vaccine is not authorized for use as a booster dose in this age group. For people ages 18 years and older, Moderna and Pfizer-BioNTech can be used as a booster dose. Currently, Novavax COVID-19 Vaccine is not authorized for booster vaccination.

‡Moderna COVID-19 Vaccine supplied in a vial with a dark blue cap and a label with a teal border stating “Age 6y through 11y” is currently not available. Moderna COVID-19 Vaccine supplied in a vial with a dark blue cap and a label with a purple border stating “**BOOSTER DOSES ONLY** Booster dose: 0.5mL” is FDA-authorized for use in children ages 6–11 years as a primary series dose.

§Vials of the Pfizer-BioNTech COVID-19 Vaccine with a maroon vial cap and maroon label border may state “Age 2y to < 5y” or “Age 6m to <5 yr.” Carton labels may state “For age 2 years to <5 years” or “For age 6 months to <5 years.” Vials with either printed age range can be used for children ages 6 months–4 years.


## COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised

For primary series and booster dose(s), an age-appropriate mRNA vaccine is preferred over the Janssen vaccine. The same mRNA vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](#)). All people ages 5 years and older should receive at least 1 booster dose if eligible (i.e., if a booster dose is FDA-approved or FDA-authorized for use in a specified population); an mRNA vaccine must be used for the second booster dose.

While this [graphic](#) is a helpful visual, it does not include clinical details necessary for administering COVID-19 vaccines. For clinical detail see the [Clinical Considerations](#) and guidance for [people who are not immunocompromised](#)

# COVID-19 Vaccination Schedule for Most People

## Number and intervals of COVID-19 vaccine doses



### Considerations for intervals for mRNA COVID-19 vaccine primary series

An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years. COVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (Pfizer-BioNTech vaccine) or 4-week (Moderna vaccine) interval between the first and second dose. A 3- or 4-week interval continues to be the recommended interval for people who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about [COVID-19 community levels](#) or an individual's higher risk for severe disease).

mRNA COVID-19 vaccines are safe and effective at the FDA-approved or FDA-authorized intervals, but a longer interval may be considered for some populations. While absolute risk remains small, the risk for myocarditis is higher for males ages 12-39 years, and this risk might be reduced by extending the interval between the first and second dose. [Some studies](#) in adolescents (ages 12-17 years) and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. Extending the interval beyond 8 weeks has not been shown to provide additional benefit. **In summary, an 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months-64 years, especially for males ages 12-39 years.**

### Transitioning from a younger to older age group

People should receive the recommended age-appropriate vaccine dosage **based on their age on the day of vaccination**. If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.

FDA authorization allows for dosing options for certain age transitions for [Pfizer-BioNTech COVID-19 Vaccine](#) and [Moderna COVID-19 Vaccine](#) as described below.

Refer to Clinical Considerations [Table 1](#) for information about age-specific vaccine products and dosages.

### Pfizer-BioNTech COVID-19 Vaccine

**Children who will turn from age 4 years to 5 years:** [FDA authorization](#) of the Pfizer-BioNTech COVID-19 Vaccine allows children who will turn from age 4 years to 5 years between any dose in the primary series to receive:

- A 2-dose primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years

or

- A 3-dose primary series initiated with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years. Each of doses 2 and 3 may be with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years, **or** the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years.

**Children who will turn from age 11 years to 12 years:** [FDA authorization](#) of the Pfizer-BioNTech COVID-19 Vaccine allows children who will turn from age 11 years to 12 years between their first and second dose in the primary series to receive, for either dose: (1) the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years or (2) the Pfizer-BioNTech COVID-19 Vaccine product authorized for people ages 12 years and older.

### Moderna COVID-19 Vaccine

**Children who will turn from age 5 years to 6 years:** [FDA authorization](#) of the Moderna COVID-19 Vaccine allows children who will turn from age 5 years to 6 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6 months–5 years or (2) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years.

**Children who will turn from age 11 years to 12 years:** [FDA authorization](#) of the Moderna COVID-19 Vaccine allows children who will turn from age 11 years to 12 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years or (2) the Moderna COVID-19 Vaccine product authorized for people ages 12 years and older.

### COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised

People with immunocompromising conditions or people who take immunosuppressive medications or therapies are [at increased risk for severe COVID-19](#). Because the immune response following COVID-19 vaccination may differ in people who are moderately or severely immunocompromised at the time of vaccination, specific guidance for this population is provided.


People who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule according to their age and immune status at the time of eligibility for doses. For example, people who become moderately or severely immunocompromised after completing a 2-dose mRNA or single-dose Janssen COVID-19 Vaccine

primary series do not need additional primary doses; however, they should follow the schedule for people who are moderately or severely immunocompromised for booster doses.

While this [graphic](#) is a helpful visual, it does not include clinical details necessary for administering COVID-19 vaccines. For clinical detail see the [Clinical Considerations](#) and guidance for [people who are immunocompromised](#).

## COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

### Number and intervals of COVID-19 vaccine doses



### CDC interactive tool for the public to assess need for first or second booster doses of COVID-19 vaccine

CDC has an interactive tool to help users identify whether they (or someone else) need to receive a booster dose of COVID-19 vaccine. The “Find Out When You Can Get Your Booster” tool asks a series of simple questions about age, immunocompromise, number and type of previous doses of COVID-19 vaccines, and how long ago they received the most recent vaccination. From these answers, the tool reports whether a first or second booster dose may be beneficial and presents considerations for when to receive it. Find the tool [here](#).

### Watch for Expired Vaccine

Providers should make it a practice to regularly check inventory for expired vaccine and immediately remove expired inventory to prevent it from being administered.

#### Vaccine Expiration Date Lookup & Reference Information:

- [Expiry Information for Pfizer COVID-19 Vaccines](#)
- [Moderna Vial Expiration Date Look-up Tool](#)
- [Janssen Expiration Date Lookup Tool](#)

#### EUA Fact Sheets









Once a new EUA Fact Sheet is issued, it must be used. Previous ones no longer contain accurate information.

#### New Novavax EUAs

- Novavax, HCP: <https://www.fda.gov/media/159897/download>
- Novavax, Recipient: <https://www.fda.gov/media/159898/download>

#### Pfizer EUAs

- Pfizer, HCP, Wall Chart Showing Different presentations: <https://www.fda.gov/media/159304/download>

Pfizer-BioNTech COVID-19 Vaccine Presentations				
Age Group	6 months through 4 years	5 through 11 years	12 years and older	12 years and older
Vial Cap Color and Label Border Color	MAROON 	ORANGE 	PURPLE** 	GRAY** 
Is Dilution Needed?	Dilute Before Use	Dilute Before Use	Dilute Before Use	Do Not Dilute
Amount of Diluent* Needed per Vial	2.2 mL	1.3 mL	1.8 mL	NO DILUTION
Dose Volume	0.2 mL	0.2 mL	0.3 mL	0.3 mL
For storage and expiry information, see FDA-authorized Fact Sheet or scan QR code.	 www.cvdvaccine-us.com	 www.cvdvaccine-us.com	 www.cvdvaccine-us.com	 www.cvdvaccine-us.com









\*Diluent: sterile 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

\*\* The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older, when prepared according to their respective instructions for use, can be used interchangeably.

- Pfizer, HCP, 6 months through 4 years, maroon cap (must dilute): <https://www.fda.gov/media/159312/download>
- Pfizer, HCP-Deer Healthcare Provider Letter, 6 months through 4 years, maroon cap (must dilute): <https://www.fda.gov/media/159303/download>
- Pfizer, Recipient, 6 months through 4 years of age: <https://www.fda.gov/media/159313/download>
- Pfizer, HCP, 12 years of age and older, purple cap (must dilute): <https://www.fda.gov/media/153713/download>
- Pfizer, HCP, 12 years of age and older, gray cap (no dilution): <https://www.fda.gov/media/153715/download>
- Pfizer, HCP, 5 - 11 years of age, orange cap (must dilute): <https://www.fda.gov/media/153714/download>
- Pfizer, Recipient, 12 years of age and older: <https://www.fda.gov/media/153716/download>
- Pfizer, Recipient, 5-11 years: <https://www.fda.gov/media/153717/download>

#### Moderna EUAs

- Moderna, HCP, Wall Chart Showing Different vials/presentations: <https://www.fda.gov/media/159306/download>

MODERNA COVID-19 VACCINE PRESENTATIONS				
Age Group	6 months through 5 years (Primary Series)	6 years through 11 years (Primary Series)  Currently unavailable (Use the vial with dark blue cap and a label with a purple border)	6 years through 11 years (Primary Series)  18 years and older (Booster Dose)	12 years and older (Primary Series)  18 years and older (Booster Dose)
Vial Cap Color	Dark Blue	Dark Blue	Dark Blue	Red
Vial Label Border Color	MAGENTA	TEAL	PURPLE	LIGHT BLUE
Vial Image				
Primary Dose Volume	0.25 mL	0.5 mL	0.5 mL	0.5 mL
Booster Dose Volume	None	None	0.5 mL	0.25 mL
For storage and expiry information, see FDA-authorized Fact Sheet or scan QR code.	 <a href="http://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>	 <a href="http://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>	 <a href="http://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>	 <a href="http://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>

- Moderna, HCP, 6 months through 5 years of age (magenta border): <https://www.fda.gov/media/159307/download>
- Moderna, Recipient, 6 months through 5 years of age (magenta border): <https://www.fda.gov/media/159309/download>
- Moderna, HCP, 6 years through 11 years of age (teal & purple border): <https://www.fda.gov/media/159308/download>
- Moderna, HCP-Dear Healthcare Provider Letter, 6 years through 11 years of age (teal & purple border): <https://www.fda.gov/media/159305/download>
- Moderna, Recipient, 6 years through 11 years of age (teal & purple border): <https://www.fda.gov/media/159310/download>
- Moderna, HCP, 12 years and older and booster doses for 18 years and older (light blue border): <https://www.fda.gov/media/157233/download>
- Moderna, Recipient, 12 years and older (black border): <https://www.fda.gov/media/144638/download>
- Moderna, HCP, 18 years and older booster dose presentation only (purple border): <https://www.fda.gov/media/157232/download>

#### Janssen EUAs

- Janssen, HCP: <https://www.fda.gov/media/146304/download>
- Janssen, Recipient: <https://www.fda.gov/media/146305/download>

## RESOURCES & LEARNING OPPORTUNITIES

### Pediatric Vaccination Toolkit for Pediatricians and Physicians

The US HHS public education campaign, [We Can Do This](#), recently launched the [Pediatricians and Family Physicians Toolkit](#) to help physicians increase confidence in and uptake of COVID-19 vaccines among their patients and in the communities they serve. Developed in partnership with the American Academy of Pediatrics, it includes information from CDC and new, culturally tailored materials, including a sample letter to parents, pediatrician talking points, posters and flyers that can be hung in offices and waiting rooms, as well as digital communications like social media posts and sample text messages.

In addition to the new toolkit, HHS has released a new PSA in [English](#) and [Spanish](#), announcing the new vaccine authorization for children 6 months and older, and a [one-pager](#) that describes some of the most effective messages when communicating with parents about the importance of the COVID-19 vaccine.

### Moderna COVID-19 Vaccine Office Hours: Pediatric and Adolescent Indications

Have questions about the Moderna COVID-19 vaccine or the recently approved pediatric and adolescent indications? Sign up for a [Q&A session](#) with one of their medical science liaisons, held on multiple days/times throughout July. These are informal, "drop-in" sessions. Join at any time during the session, get your questions answered, and get back to your day!

### Pfizer COVID-19 Vaccine Medical Updates on Current & Immunization Site Training

Pfizer Vaccines US Medical Affairs continues to host frequent Medical Updates & Immunization Site Training for All Providers. Session topics include:

- Use of vaccine for Children 6 months and older
- Storage, Handling, Preparation, & Administration for the multiple presentations of the vaccine
- Recent medical updates regarding the vaccine
- An overview of healthcare provider resources
- Question and answer session

To access the training sessions, please visit: <https://www.pfizermedicalinformation.com/en-us/medical-updates>

### COVID-19 Vaccine Training Modules

CDC's four training modules (General Overview, Pfizer, Moderna, Janssen) can be found [here](#).

### COVID-19 Vaccine Webinar Series

CDC is offering a series of brief (15-20 minute) webinars addressing topics around COVID-19 vaccination. These interactive, web-based training modules offer a real-world perspective on different issues around COVID-19 vaccines. Topics range from routine clinical and vaccine safety information to guidance for on-site clinic vaccination activities and having conversations with vaccine recipients. Each webinar includes self-test practice questions and lists additional resources related to the topic discussed. The landing page for all mini webinars is here: <https://www.cdc.gov/vaccines/covid-19/training-education/webinars.html>

### CDC "Interactive COVID-19 Vaccine Conversations Module for Healthcare Professionals"

CDC has a resource to equip healthcare professionals with the tools they need to have effective COVID-19 vaccine conversations with patients. The [Interactive COVID-19 Vaccine Conversations Module for Healthcare Professionals](#) includes:

- Tips for Having Effective Vaccine Conversations with Patients
- Vaccine Conversations in Practice: Case Scenarios

**Morbidity and Mortality Weekly Report**, better known as MMWR, is CDC's primary publication for disseminating the science it produces. The staff at MMWR have launched a [landing page](#) to help people find the latest information on COVID-19 vaccine effectiveness and safety.

### Recent CDC MMWRs

#### July 15, 2022 (EARLY RELEASE)

- [Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022](#)

#### July 15, 2022

- [Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022](#)

## MDPH RESOURCES

### Massachusetts Resources

- COVID-19 vaccinations for [children ages 6 months to 4 years old](#)
- COVID-19 vaccinations for [children ages 5-11](#)
- COVID-19 vaccinations for [people ages 12-17](#)

- COVID-19 [Vaccine Information](#)
- COVID-19 [booster information](#) and [booster frequently asked questions](#)
- Search for Vaccine locations: <https://vaxfinder.mass.gov/>
- COVID-19 Vaccine Resource Line/2-1-1 is available for individuals who are unable to use Vaxfinder, or have difficulty accessing the internet. Available in English and Spanish and has translators available in approximately 100 additional languages.
- COVID-19 Vaccine Training and Education Resources for Providers: <https://www.mass.gov/info-details/covid-19-vaccine-training-and-education-resources-for-providers>
- [Multilingual COVID-19 Materials](#). Resources related to Coronavirus Disease 2019 (COVID-19) in multiple languages. Includes videos and printables on topics like vaccine safety, pregnancy and the vaccine, and FAQs.

#### **Immunization Division Main Number**

For questions about immunization recommendations, disease reporting, etc.

Phone: 617-983-6800 (24/7 MDPH Epi line)

Fax: 617-983-6840

Website: <https://www.mass.gov/topics/immunization>

#### **MIIS Help Desk**

Phone: 617-983-4335

Fax: 857-323-8321

Email questions to: [miishelpdesk@mass.gov](mailto:miishelpdesk@mass.gov)

Website: <https://www.mass.gov/massachusetts-immunization-information-system-miis>

#### **MDPH Vaccine Unit**

Phone: 617-983-6828

Email questions to: [dph-vaccine-management@mass.gov](mailto:dph-vaccine-management@mass.gov)

Website: <https://www.mass.gov/service-details/vaccine-management>

#### **COVID-19 Email Box**

Email questions to: [COVID-19-Vaccine-Plan-MA@mass.gov](mailto:COVID-19-Vaccine-Plan-MA@mass.gov)